Table 2.
DNA methylation biomarkers for Barrett’s esophagus and esophageal adenocarcinoma.
| Reference | Biomarker | Study design | Samples (case/control) | Results | Clinical application |
|---|---|---|---|---|---|
| Moinova H.R. et al., 2018 (75) | CCNA1, VIM | Observational study | 173 + 149 (validation cohort) | CCNA1 with AUC 0.95 (BE vs. controls) CCNA1 + VIM showed 90.3% sensitivity and 91.7% specificity |
BE screening |
| Yu M. et al., 2015 (73) | B3GAT2, ZNF793 | Observational study | 98 + 66 (validation cohort) | B3GAT2 - ZNF793 methylation rates: 32.5% - 31.1 (BE patients) vs. 2.19% - 2.52 (controls) (p < 0.0001) | BE screening |
| Chettouh H. et al., 2018 (76) | TFPI2 | Pilot study | 30 + 278 (validation cohort) | TFPI2 sensitivity 82.2%–specificity 95.7% | BE screening |
| Maity A.K. et al., 2022 (77) | CTNND2, CCL20 | Retrospective study | 407 | CTNND2 inactivated in BE – CCL20 overactivated in EAC | EAC screening |
| Schulmann K et al., 2005 (78) | p16, RUNX3, HPPI | Retrospective study | 234 | p16 (OR 1.74, 95%CI 1.33–2.20), RUNX3 (OR 1.80, 95%CI 1.08–2.81), HPPI (OR 1.77, 95%CI 1.06–2.81) | EAC screening |
| Jin Z. et al., 2009 (79) | p16 + RUNX3 + HPP1 + NELL1 + TAC1 + SST + AKAP12 + CDH13 | Retrospective study | 195 | Sensitivity 50%–specificity 90% | Progression risk |
| Alvi M.A. et al., 2013 (80) | SLC22A18, PIGR, GJA12, RIN2 | Retrospective study + prospective multicentric study | 186 (retrospective cohort), 135 (prospective cohort) | AUC 0.98 | EAC screening |
BE, Barrett’s esophagus; EAC, esophageal adenocarcinoma; AUC, area under the curve; OR, odds ratio; CI, confidential interval.